Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

46.26
+0.06000.13%
Pre-market: 46.11-0.1500-0.32%04:31 EDT
Volume:3.76M
Turnover:173.88M
Market Cap:3.48B
PE:-13.54
High:46.26
Open:46.19
Low:46.16
Close:46.20
Loading ...

SpringWorks Therapeutics Shares up 6% Premarket Ahead of Q4 Results

THOMSON REUTERS
·
20 Feb

SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors

TIPRANKS
·
19 Feb

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Zacks
·
14 Feb

SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25

TipRanks
·
13 Feb

SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
13 Feb

SpringWorks Therapeutics CEO sells $2.56M in common stock

TIPRANKS
·
13 Feb

Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon

TIPRANKS
·
13 Feb

SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg

TIPRANKS
·
13 Feb

SpringWorks Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
12 Feb

SpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder

MT Newswires Live
·
12 Feb

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Springworks Therapeutics (SWTX)

TIPRANKS
·
12 Feb

Update: SpringWorks Therapeutics Announces FDA Approval of Gomekli™ (Mirdametinib) for the Treatment of Adult and Pediatric Patients With Nf1-Pn

THOMSON REUTERS
·
12 Feb

Stock Track | SpringWorks Therapeutics Soars 7% After-Hours on FDA Approval for Rare Disease Drug, Merck Acquisition Talks

Stock Track
·
12 Feb

BRIEF-Springworks Therapeutics Announces FDA Approval Of Gomekli (Mirdametinib) For Treatment Of Adult And Pediatric Patients With NF1-PN

Reuters
·
12 Feb

SpringWorks Therapeutics confirms FDA approval of Gomekli

TIPRANKS
·
12 Feb

SpringWorks Therapeutics Announces FDA Approval of Gomekli™ (Mirdametinib) for the Treatment of Adult and Pediatric Patients With Nf1-Pn

THOMSON REUTERS
·
12 Feb

Stock Track | SpringWorks Therapeutics Plunges 5.98% After Hours on Profitability Concerns Over Potential Merck Acquisition

Stock Track
·
12 Feb

US FDA approves SpringWorks' genetic disorder drug

Reuters
·
12 Feb

BRIEF-FDA Approved Mirdametinib, For Adult & Pediatric Patients 2 Years Of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable To Complete Resection

Reuters
·
12 Feb

US FDA approves Springworks' genetic disorder drug

Reuters
·
12 Feb